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SUMMARY AT A GLANCE 
We prospectively evaluated 638 COPD patients and provide evidence that COPD patients receiving anti-acid 
therapy with PPI for GERD remain at high risk of frequent and severe exacerbations independently of adjusted 
Charlson score, FEV1% predicted, BODE index, MMRC and medication for comorbidities. 
ABSTRACT 
Background and objective: Gastroesophageal reflux disease (GERD) symptoms are associated with a higher risk 
of chronic obstructive pulmonary disease (COPD) exacerbation. We hypothesize that treatment with proton 
pump inhibitors reduces the risk of exacerbation in patients witii stable COPD. 
Methods: A total of 638 patients wim stable COPD for ≥6 weeks, ≥10 pack-years of smoking and Global 
Initiative for Chronic Obstructive Lung Disease Π-IV seeking care in tertiary hospitals in eight European 
countries in the Predicting Outcome using Systemic Markers in Severe Exacerbations-COPD cohort was 
prospectively evaluated by us. Comorbidities including associated medical treatment were assessed at baseline, 
at exacerbation and at biannual visits. Median observation time was 24 months. The primary study outcomes 
were exacerbation and/or death. 
Results: A total of 85 (13.3%) of COPD patients were on anti-GERD therapy. These patients had higher annual 
and higher severe exacerbation rates (P = 0.009 and P = 0.002), decreased quality of life (SF-36: activity score P 
= 0.004, St. George's Respiratory Questionnaire: physical functioning P = 0.013 and social functioning P = 
0.007), higher body mass airflow obstruction, dyspnea and exercise capacity index (P = 0.033) and Modified 
Medical Research Council scores (P = 0.002), shorter 6-min walking distance (P = 0.0004) and a higher adjusted 
Charlson score (P < 0.0001). Anti-GERD therapy was associated with a shorter time to severe exacerbation   
(HR 2.05 95% CI 1.37-3.08). Using three multivariable Cox-regression models, this association was independent 
of the following: (i) adjusted Charlson score and FEV1% predicted (HR 1.91 95% CI 1.26-2.90); (ii) adjusted 
Charlson score, body mass, airflow obstruction, dyspnea and exercise capacity index and Modified Medical 
Research Council (HR 1.62 95% CI 1.04-2.54); and (iii) adjusted Charlson score, FEV1% predicted and nine 
classes of medication for comorbidities (HR 1.63 95% CI 1.04-2.53). 
Conclusion: These findings suggest that patients with stable COPD receiving acid-suppressive therapy with 
proton pump inhibitors remain at high risk of frequent and severe exacerbations. 
Keywords : anti-gastroesophageal reflux disease therapy ; chronic obstructive pulmonary disease ; chronic 
obstructive pulmonary disease exacerbations ; gastroesophageal reflux disease ; proton pump inhibitors. 
Abbreviations : 6MWD, 6-min walking distance ; AECOPD, acute exacerbations of COPD ; BODE index, 
body mass, airflow obstruction, dyspnea and exercise capacity inde x; CI, confidence intervals ; COPD, chronic 
obstructive pulmonary disease ; FEV1, forced expiratory volume in 1 s ; FVC, forced vital capacity ; GERD, 
gastroesophageal reflux disease ; GOLD, Global Initiative for Chronic Obstructive Lung Disease ; HR, hazard 
ratio ; MMRC, Modified Medical Research Council ; post-brd, post-bronchodilated ; PPI, proton pump inhibitors 
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; PROMISE-COPD, Predicting Outcome using Systemic Markers in Severe Exacerbations of Chronic 
Obstructive Pulmonary Disease Study. 
 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality 
characterized by airflow limitation that is usually progressive and associated with chronic inflammation in the 
airways and the lung.
1,2
 The accelerated deterioration of pulmonary function in COPD may occur at any stage, 
and the associated episodes are called acute exacerbations of COPD (AECOPD). Frequent AECOPD hasten lung 
function decline,
3
 reduce quality of life and contribute significantly to mortality and morbidity.
4,5
 AECOPD can 
be triggered by viral or bacterial infections
6,7
 and stimulate both airway and systemic inflammatory responses.
8,9
 
Chronic obstructive pulmonary disease is associated with a number of comorbidities such as gastroesophageal 
reflux disease (GERD) with a prevalence of about 10-29% in Western population.
10-13
 GERD is denned as a 
condition of reflux of stomach contents causing symptoms like postprandial heartburn and regurgitation, often 
occurring at night.
14
 A low-lying diaphragm due to hyperinflation,
15
 cough and the increased use of abdominal 
muscles predicts GERD in COPD patients. GERD is associated with extra-oesophageal symptoms of chronic 
cough, hoarseness, laryngitis and dental erosions. Epidemiologic studies show a moderate association between 
GERD and a range of pulmonary symptoms.
16
 
The prevalence of GERD symptoms in patients with COPD ranges from 16.5-60%.
17-20
 Patients with GERD 
have impaired cough-related quality of life and more COPD symptoms.
21
 As COPD is also a common chronic 
disease, there is a great effort to evaluate the potential association between these two diseases and whether the 
presence of GERD increases the prevalence of COPD and its exacerbation or vice versa. The recent ECLIPSE 
study, which included 2138 COPD patients, showed that reflux symptoms are an independent predictor of 
frequent exacerbations and postulated a phenotype of susceptibility to exacerbation.
22
 It is unknown whether 
treatment of GERD could decrease the susceptibility to AECOPD. We hypothesized that treatment of GERD 
with proton pump inhibitors (PPI) reduces the risk of exacerbations in stable COPD. 
METHODS 
Study design 
The present study was based on data collected from the Predicting Outcome using Systemic Markers in Severe 
Exacerbations of Chronic Obstructive Pulmonary Disease cohort (PROMISE-COPD; ISRCTN99586989), which 
is an investigator-driven, multicenter, longitudinal observational study. The PROMISE-COPD study was 
approved by the ethics committees of all the participating centres. All patients provided written informed consent 
for study assessments, and the study was conducted in accordance with the Good Clinical Practice guidelines. 
Patients 
We consecutively recruited 638 patients with moderate to very severe COPD, who were clinical stable and at 
least 4 weeks after an exacerbation. All patients were ≥40 years old, current or ex-smokers with a smoking 
history of ≥10 pack-years. Exclusion criteria were a life expectancy of less than 6 months, pulmonary condition 
other than COPD, immunosuppression including organ transplantation or chronic steroid use (>20 mg 
prednisolone equivalent per day) and muscle-skeletal or neuromuscular process preventing ambulation. 
At baseline, patients underwent sputum analysis and standard spirometry. The severity of obstruction and 
condition of the patients was graded according to the stages of disease defined by the Global Initiative for 
Chronic Obstructive Lung Disease. Each patient underwent 6-min walking distance (6MWD) testing and 
provided information on quality of life questionnaire (St. George's Respiratory Questionnaire, SF-36). 
Furthermore, a Modified Medical Research Council dyspnea score (MMRC), body mass, airflow obstruction, 
dyspnea and exercise capacity (BODE index score)
23
 and age-adjusted Charlson score were performed for each 
patient. Comorbidities including associated medical therapy were assessed at baseline, at exacerbation and at 
biannual visits. After the baseline visit, patients had scheduled visits every 6 months and unscheduled visits at 
exacerbation and 4 weeks later. The median follow-up was 24 months. 
Reflux was defined as post-prandial heartburn and symptomatic regurgitation. Exacerbations were denned as an 
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acute event characterized by a worsening of respiratory symptoms leading to a change in medication. Episodes 
requiring hospitalization were denned as severe exacerbations. The exacerbation frequency was observed over a 
period of 24 months. 
The cohort of 638 patients was divided in two groups. One group included 85 patients (13.3%) with GERD and 
receiving PPI. The other group included 553 (86.7%) patients that did not meet the criteria of GERD and were 
not receiving PPI. A total of 75 patients from the first and 500 patients from the second group completed the 
median follow-up of 2 years (Fig. 1). 
Statistical analysis 




The baseline demographic and clinical characteristics of the patients are shown in Table 1. Most common drugs 
used for GERD treatment were esomeprazole (45%), pantoprazole (27%) and omeprazole (20%). Most patients 
receiving GERD treatment at baseline were still receiving the same drugs during the follow-up period of the 
study. Patients receiving therapy for GERD and patients not receiving therapy for GERD had similar 
demographic and clinical characteristics. However, the cohort receiving GERD therapy had higher BODE index 
(P = 0.033), higher MMRC scores (P = 0.002), a shorter 6MWD (P = 0.0004) and higher adjusted Charlson 
score (P < 0.0001). 
The majority of patients (62.2%) reported sputum production in most days of the year. Positive sputum 
bacteriology was identified in 32.2% of the 155 patients that underwent sputum sampling without significant 
differences between the two groups of patients (Table 1). 
Most COPD patients received combined therapy with short acting β 2 agonists and short acting muscarinic 
antagonists or long acting β 2 agonists and inhaled corticosteroids or long acting muscarinic antagonists. There 
were no significant differences in the medication between the groups (Table 2). 
Cardiovascular diseases, pulmonary hypertension, diabetes mellitus and renal failure were the most common 
comorbidities (Supplementary Table S1). There was a higher incidence of arterial hypertension, congestive heart 
failure, diabetes mellitus and renal failure in the group on therapy for GERD, as compared with the non-
treatment group. The GERD treatment group had a decreased quality of life (SF-36: activity score P = 0.004, St. 
George's Respiratory Questionnaire: physical functioning P = 0.013 and social functioning P = 0.007) 
(Supplementary Table S2). 
 
Figure 1  Flow chart for the present analysis. COPD, chronic obstructive pulmonary disease; GERD, 
gastroesophageal reflux disease; PROMISE-COPD, Predicting Outcome using Systemic Markers in Severe 
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Table 1    Baseline demographic and clinical characteristics according to the use of PPI in 685 patients with 
GOLD II—IV, at stable state, included in the PROMISE study 
  Medication for GERD  
Characteristic All n = 638 No (n = 553) Yes (n = 85) P value 
Age, years 67 (60-74) 67 (60-74) 69 (61.5-76.5) 0.038 
Male, n (%) 448 (70.2%) 388(70.1%) 60 (70.6%) 1.000 
Caucasian, n (%) 632 (99.1%) 547 (98.9%) 85 (100%) 1.000 
Current smoker, n (%) 213 (33.4%) 185 (33.5%) 28 (32.9%) 1.000 
Pack-years (mean ± SD) 50.2±29.9 51.2±32.9 53.5±23.3 0.468 
Duration of COPD symptoms, months 
(mean±SD) 
104.6±89 106.6±87.4 74±62.4 0.925 
Time elapse since diagnosis, months 
(mean±SD) 
80.9±76.3 81.9±74.4 108.2±95.5 0.749 
BMI (kg/m
2
) (mean±SD) 26.6±5.5 26.6±5.8 25.0±27.6 0.113 
MMRC grade 2 (1-3) 1 (1-2) 2 (1-3) 0.002 
6MWD (m) (mean±SD) 379±105 378±109 338±109 0.005 
BODE index 3 (1-4) 3 (1-4) 4 (2-6) 0.033 
Age-adjusted Charlson score 4 (3-5) 4 (3-5) 4 (3-6) <0.001 
GOLD grade, n (%)     
II 303 (47.5%) 269 (48.6%) 34 (40%) 0.294 
III 217 (34%) 184 (33.3%) 33 (38.8%)  
IV 101 (15.8%) 84 (15.2%) 1 7 (20%)  
FVC, post-brd, % predicted 77.0±24 78.5 ±24.5 78.2±24.7 0.119 
FEV1, post-brd, % predicted 48.9±18.2 48.0±18.7 44.0±17.6 0.061 
FEV1/FVC post-brd % 48.5±14.0 47.9±14 42.6±12.1 0.046 
Bronchitic phenotype n (%) 397 (62.2%) 346 (62.6%) 51 (61.4%) 0.719 
Positive sputum bacteriology n (%) 50/155 (32.2%) 40/134 (29.9%) 10/21 (47.6%) 0.132 
6MWD, 6-min walking distance; BMI, body mass index; BODE index, body mass, airflow obstruction, dyspnea and exercise capacity index; 
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GERD, 
gastroesophageal reflux disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; MMRC, Modified Medical Research 
Council; PPI, proton pump inhibitor; post-brd, post-bronchodilated; PROMISE, Predicting Outcome using Systemic Markers in Severe 
Exacerbations; SD, standard deviation. 
 
Clinical outcome 
Within the 2 years follow-up period, significantly more patients in the group receiving therapy for GERD had 
exacerbations (P = 0.009), severe exacerbations per year (P = 0.002) and more frequent severe exacerbations (P 
= 0.014) (Table 3). Using univariate Cox-regression analysis, we observed that anti-GERD therapy was 
associated with a significant (P < 0.0001) shorter time to severe exacerbation, with a hazard ratio of 2.05 (95% 
CI: 1.37-3.08) (Table 4). Furthermore, several factors such as BODE index (P < 0001), its subdomains' MMRC 
grade (P = 0.001), 6MWD (P < 0.001), a history of lung volume reduction procedures (P = 0.017), congestive 
heart failure (P = 0.013) and a lower FEV1/FVC % ratio post-bronchodilatation (P = 0.002) were associated with 
a shortened time to severe AECOPD. 
Multivariate Cox-regression analysis revealed that anti-GERD therapy was significantly associated with time to 
severe exacerbation in COPD, independently of BODE index, supervised rehabilitation, lung volume reduction 
procedure and congestive heart failure (HR 1.58, 95% CI: 1.01-2.47); adjusted Charlson score and FEV1% 
predicted (HR 1.91, 95% CI: 1.26-2.91); and adjusted Charlson score, FEV1% predicted and nine classes of 
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Table 2    COPD-specific treatment according to the use of PPI in 685 patients with GOLD II—IV, at stable 
state, included in the PROMISE study 
 All (n = 638) Medication for GERD P value 
No (n = 553) Yes (n = 85) 
Pharmacological treatment     
SABA/SAMA 115 (18.0%) 105 (18.9%) 10 (11.8%) 0.129 
LABA/ICS 450 (70.5%) 388 (70.2%) 62 (72.9%) 0.702 
SABA 183 (28.7%) 156 (28.2%) 27 (31.8%) 0.520 
LAMA 423 (66.3%) 362 (64.5%) 61 (71.8%) 0.270 
ICS 72 (11.3%) 64 (11.6%) 8 (9.4%) 0.713 
Methylxanthines 66 (10.3%) 59 (10.7%) 7 (8.2%) 0.571 
Mucolytics/antioxidants 74 (11.6%) 60 (10.8%) 14 (16.5%) 0.145 
Non-pharmacological 
treatment 
    
Supervised rehabilitation 150 (23.5%) 122 (22.1%) 28 (32.9%) 0.038 
Oxygen therapy 123 (19.3%) 102 (18.4%) 21 (24.7%) 0.184 
Non-invasive ventilation 27 (4.2%) 21 (3.8%) 6 (7.0%) 0.156 
COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; GOLD, Global Initiative for Chronic Obstructive 
Lung Disease; ICS, inhaled corticosteroids; LABA, long acting β 2 agonists; LAMA, long acting muscarinic antagonists; PPI, proton pump 
inhibitor; PROMISE, Predicting Outcome using Systemic Markers in Severe Exacerbations; SABA, short acting β 2 agonists; SAMA, short 
acting muscarinic antagonists. 
 
Table 3    Clinical outcomes according to the use of PPI in 685 patients with GOLD II—IV, at stable state, 
included in the PROMISE study in COPD patients 
  Medication for GERD P 
value Clinical outcome All (n = 638) No (n = 553) Yes (n = 83) 
Exacerbations per year median (interquartile range) 0.72 (0-1.8) 0.67 (0-1.8) 1.03 (0-3.4) 0.009 
Severe exacerbation per year median (interquartile 
range) 
0 (0-0) 0 (0-0) 0 (0-0.5) 0.002 
Time to exacerbation median (interquartile range) 338 (135-697) 336 (133-392) 310 (135-730) 0.484 
Time to severe exacerbation median (interquartile 
range) 
701 (342-748) 710 (364-749) 518 (187-748) 0.014 
Time to death median (interquartile range) 722 (395-762) 725 (393-763) 719 (418-758) 0.708 
COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; GOLD, Global Initiative for Chronic Obstructive 
Lung Disease; PPI, proton pump inhibitor; PROMISE, Predicting Outcome using Systemic Markers in Severe Exacerbations. 
 
DISCUSSION 
In the present study, we included 638 COPD patients enrolled in the large observational PROMISE cohort, to 
examine the potential association of anti-GERD therapy on AECOPD. We report that therapy for GERD is an 
independent factor associated with shorter time to severe exacerbation in COPD patients. 
Acute exacerbations of COPD impact on patient morbidity and mortality
2
 and pose a considerable economic 
burden for healthcare systems. Despite the negative impact of AECOPD on the natural course of the disease, 
there is inadequate information regarding their causes. Recent studies suggest the main determinants for 
AECOPD are the severity of the disease, previous history of exacerbations and the presence of comorbidities 
such as congestive heart failure, coronary artery disease, chronic renal/liver failure and GERD.
24
 A 'frequent 
exacerbator phenotype' has been described, which is independent of disease severity and associated with a poorer 
health outcome with former exacerbations being the strongest trigger for AECOPD.
25
 A higher exacerbation rate 
in patients with GERD symptoms has been shown in a North American cohort,
26
 an observation that was also 
confirmed in two prospective Japanese studies
20,27
 and a Chinese study
28
 These findings were found to be 
independent of other triggers for AECOPD, such as respiratory infection, airway obstruction and congestive 
heart failure. 
Should GERD be a major trigger for AECOPD, one would expect that treatment with PPI would reduce 
exacerbations in COPD patients. Yet in our study, patients on anti-GERD therapy with PPI had higher annual 
exacerbation rates, as well as higher severe exacerbation rates. Our findings are in accordance with a 
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retrospective population-based study, which demonstrated that newly diagnosed GERD is an independent risk 
factor for AECOPD in the first 12 months and despite treatment, these patients are at higher risk of AECOPD-
related emergency consultations and hospitalizations.
29
 If treatment was efficacious, a possible explanation of 
our findings might be that PPI do not stop reflux; rather, they render reflux non-acidic or weakly acidic, which 
has been shown to contribute to pulmonary symptoms.
30
 Patients with asthma had more regurgitation-related 





Table 4    Crude hazard ratio for time to next severe exacerbation in 685 patients with GOLD II—IV, at stable 
state, included in the PROMISE study 
Characteristics HR (95% CI) P value 
Anti-GERD therapy 2.05 (1.37-3.08) <0.001 
Age, years 1.02 (1.00-1.93) 0.058 
Current smoking 1.25 (0.85-1.82) 0.257 
MMRC grade 1.28 (1.11-1.48) 0.001 
6MWD 0.99 (0.99-0.99) <0.001 
BODE index 1.20 (1.11-1.30) <0.001 
Supervised rehabilitation 1.46 (1.02-2.10) 0.041 
Volume reduction therapy 2.19 (1.15-4.11) 0.017 
Adjusted Charlson score 1.07 (0.98-1.15) 0.169 
Arterial hypertension 1.13 (0.81-1.57) 0.489 
Congestive heart failure 1.68 (1.12-2.53) 0.013 
Malignancy 1.28 (0.60-2.73) 0.528 
Diabetes mellitus 1.57 (0.39-6.37) 0.524 
Renal failure 1.76 (1.00-3.12) 0.052 
Acetosalicylic acid/clopidogrel 1.24 (0.88-1.74) 0.218 
Diuretics 1.53 (1.08-2.16) 0.016 
ACE-inhibitors/AT-ll antagonists 1.12 (0.80-1.58) 0.511 
β-blockers 1.28 (0.87-1.89) 0.215 
Antidepressives 1.38 (0.86-2.21) 0.188 
FEV1/FVC% post-brd, % 0.98 (0.76-0.99) 0.002 
6MWD, 6-min walking distance; anti-GERD therapy, proton pump inhibitors; BODE, body mass, airflow obstruction, dyspnea and exercise 
capacity; CI: confidence intervals; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GERD, gastroesophageal reflux 
disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, hazard ratio; MMRC: Modified Medical Research Council; 
PPI, proton pump inhibitors; post-brd, post-bronchodilated; PROMISE, Predicting Outcome using Systemic Markers in Severe 
Exacerbations. 
 
Table 5    Multivariate Cox-regression analysis for time to next severe exacerbation in 685 patients with GOLD 
II—IV, at stable state, included in the PROMISE study 
Model 1 -LLH 1468χ2 36.23 5 df HR (95% CI) P value 
Anti-GERD therapy 1.58 (1.01-2.47) 0.044 
BODE index 1.18 (1.09-1.27) <0.001 
Supervised rehabilitation 1.15 (0.77-1.71) 0.503 
Lung volume reduction procedure 1.42 (0.71-2.81) 0.320 
Congestive heart failure 1.48 (0.95-2.30) 0.083 
Model 2 - LLH 1649χ2 22.5 3df   
Anti-GERD therapy 1.91 (1.26-2.91) 0.002 
Adjusted Charlson score 1.04 (0.96-1.13) 0.370 
FEV1, % predicted 0.99 (0.98-0.995) 0.002 
Model 3-LLH 1605χ2 24.89 12df   
Anti-GERD therapy 1.63 (1.04-2.53) 0.032 
Adjusted Charlson score 0.99 (0.90-1.010) 0.882 
FEV1, % predicted 0.99 (0.98-0.99) 0.002 
Medication for comorbidities   
Aspirin 1.04 (0.70-1.55) 0.838 
Statins 0.998 (0.65-1.54) 0.991 
Diuretics 1.45 (0.98-2.13) 0.061 
Published in : Respirology (2016), vol. 21, pp. 883-890. 
Status : Postprint (Author’s version) 
 
ACE-inhibitors/AT-ll antagonists 1.04 (0.71-1.54) 0.829 
Ca-antagonists 0.97 (0.61-1.52) 0.879 
β-blockers 1.25 (0.83-1.89) 0.292 
Antidepressives 1.29 (0.79-2.11) 0.306 
Oral antidiabetics 1.01 (0.55-1.84) 0.975 
Insulin 0.93 (0.37-2.35) 0.879 
Anti-GERD therapy, proton pump inhibitors; BODE index, body mass, airflow obstruction, dyspnea and exercise capacity index; CI: 
confidence intervals; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; GOLD, 
Global Initiative for Chronic Obstructive Lung Disease; post-brd, post-bronchodilated; PROMISE, Predicting Outcome using Systemic 
Markers in Severe Exacerbations. 
 
Another hypothesis, explaining how airway obstruction may predispose to GERD, was described using Boyle's 
Law and Bernoulli's Principle.
32
 Boyle's Law predicts that the oesophagus is kept collapsed by the maximal 
negative thoracic pressure during end-inspiration and consecutively, on the other side of the diaphragm, 
abdominal pressure is increased. In airways obstruction, more negative thoracic pressure is required for 
inspiration resulting in positive abdominal pressure. Therefore, increased intra-abdominal pressure might 
compromise the anti-reflux barrier by forcing stomach contents through the lower oesophageal sphincter, which 
is relaxed during swallowing in response to pharyngeal and oesophageal distension.
33 
This effect might be 
aggravated by a decreased low-oesophagus sphincter pressure because of β agonists.34 Gadel et al.35 measured a 
high prevalence of oesophageal motility disorders in COPD patients and found a negatively correlation of upper 
and lower oesophageal sphincter pressure to indices of hyperinflation. Furthermore, Turbyville
32
 suggested that 
Bernoulli's Principle in upper airway obstruction may be the cause of air shunting into the oesophagus and 
compromising the anti-reflux barrier from above by a suction effect. 
Treating GERD with acid reduction can be beneficial to control symptoms. However, GERD is not only caused 
by acid over-production but it is also associated with a mechanical breach and physical effect of the anti-reflux 
barrier. The aforementioned hypothesis may explain why COPD can predispose to GERD, and once GERD 
develops, the risk for AECOPD persists even after anti-reflux therapy is started.
35
 Thus, as long as patients 
remain obstructive, they will have reflux, and that is why anti-GERD therapy may not be the final solution to 
emerge reflux in airway obstruction. 
It remains unclear if there is a causative mechanism involving micro aspiration of stomach contents, leading to 
increased airway inflammation and AECOPD. Interestingly, patients receiving treatment for GERD did not have 
a higher colonization rate in sputum samples, indicating that bacterial colonization does not seem to be a major 
factor contributing to AECOPD in patients on anti-GERD therapy. Another hypothesis suggests that the vagal-
mediated oesophago-bronchial reflux may provoke bronchoconstriction
36
, but as mentioned, GERD may be the 
result of other causes than acid effect. Alternatively, the use of PPI could be a marker of disease severity, its 
comorbidities and/or related medication. This hypothesis is less convincing because the association of PPI with 
exacerbation remained significant after adjusting for multiple characteristics of severity in COPD. However, in 
the absence of randomized data, it cannot be fully refuted. Hyperinflation is a factor that can intensify GERD 
symptoms, but after adjustment for lung volume reduction procedures, anti-GERD therapy remained 
significantly associated with a shorter time to severe AECOPD. Further investigations are required to explore 
how non-acid (laryngeal) reflux and dynamic lung hyperinflation influence AECOPD. 
In a randomized, single-blind, non-placebo controlled trial involving 100 elderly ex-smokers without GERD, 
treatment with lansoprazole was associated with a significant decrease in AECOPD within a period of 12 
months.
37
 However, in asthma patients with GERD, treatment with esomeprazole once or twice daily did not 
improve asthma outcomes.
38
 Furthermore, it has been shown that in patients with duodenal ulcer disease infected 
with Helicobacter pylori, treatment with omeprazole decreased significantly the production of proinflammatory 
and inflammatory cytokines in PHA-cultured peripheral blood lymphocytes.
39
 In a recent study, it has been 
shown that patients with COPD and GERD, who did not use acid inhibitory treatment regularly, had an increased 
risk of COPD exacerbations during follow-up as compared with those who used acid inhibitory treatment 
regularly.
40
 However, in this study, the authors used questionnaires to define GERD and AECOPD were denned 
by the use of corticosteroids alone or in combination with antibiotics. Furthermore, comparison was made 
between patients with COPD and GERD without treatment with PPI and patients with COPD and GERD 
receiving treatment with PPI, while in our study, we compared time to severe exacerbations between COPD 
patients and COPD patients with GERD treated with PPI. 
Our study has a few limitations. It was not placebo controlled, and anti-GERD therapy was decided according to 
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clinical findings. GERD was not objectively diagnosed by 24-h oesophageal pH-monitoring, which is the Global 
Initiative for Chronic Obstructive Lung Disease standard to diagnose acid regurgitation. We may have missed 
reflux in the control group, because many episodes of reflux are asymptomatic and are only detected by 
oesophageal manometry.
41
 It would be interesting to use laryngeal pH-metry in combination with manometry to 
prospectively select asymptomatic patients with COPD having reflux for future intervention studies. We believe, 
however, that potentially, patients with a more severe disease (i.e. symptomatic reflux) would tend to benefit 
more from therapy than those with subclinical or minimal disease. Our study can be seen as a hypothesis 
generating analysis of a cohort study specifically designed to assess factors associated with exacerbation risk in 
COPD. Due to study design, the two groups of patients were not matched in size, COPD severity, comorbidities 
and concomitant therapies. Thus, a prospective, placebo-controlled design would be the preferable design to 
answer if PPI reduce the frequency of exacerbations in COPD patients with GERD symptoms. 
Study strengths include its prospective design, a full characterization of the patient population and the long-term 
follow-up. Furthermore, we assessed many measurable parameters that may influence the main finding, which is 
the association of anti-GERD therapy with a shorter time to severe exacerbation in patients with stable COPD, 
like the following: (i) quality of life including activity score, physical functioning and social functioning; (ii) 
BODE index; (iii) MMRC scores; (iv) 6-min walking distance; (v) adjusted Charlson score (i.e. age and 22 
comorbidities); and (vi) medication for the treatment of the comorbidities. We have analysed the aforementioned 
parameters with three multivariable Cox-regression models and concluded that the association of anti-GERD 
therapy with a shorter time to severe exacerbation was independent of the parameters included in the three 
models. Even if we cannot exclude that other unknown factors, associated with the exacerbation rate, may have 
influenced our results, we believe that it is fair to state that we have excluded a high number of confounding that 
could have accounted for the findings in our study by adjusting for known COPD characteristics associated with 
exacerbation risk and exploring different statistical models, which adjusted for those characteristics. However, 
these adjustments, by far, do not allow for the degree of certainly provided by a randomized controlled trial. 
In conclusion, the findings suggest that patients with stable COPD receiving acid-suppressive therapy with a PPI 
are at high risk of frequent and severe exacerbations. However, due to study design, our conclusions should be 
consciously interpreted and confirmed with a randomized, placebo-control study. 
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